Australia markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3500+0.0900 (+7.14%)
At close: 04:00PM EDT
1.3500 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2600
Open1.2700
Bid1.3300 x 100
Ask1.4000 x 100
Day's range1.2700 - 1.3800
52-week range1.1400 - 5.2000
Volume136,068
Avg. volume227,803
Market cap79.492M
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

    InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging study expected by the end of 2024, with data availability anticipated in 2025 InflaRx is considering partnership options for

  • GlobeNewswire

    InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

    JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results

  • GlobeNewswire

    InflaRx Appoints Jan Medina as Head of Investor Relations

    JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels